Advertisement
Research Article

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

  • Christopher M. O'Connor mail,

    christophe.oconnor@duke.edu

    Affiliation: Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina, United States of America

    X
  • Mona Fiuzat,

    Affiliation: Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina, United States of America

    X
  • Peter E. Carson,

    Affiliation: Division of Cardiology, Department of Veterans Affairs, Washington, District of Columbia, United States of America

    X
  • Inder S. Anand,

    Affiliation: Division of Cardiology, Department of Veterans Affairs, Minneapolis, Minnesota, United States of America

    X
  • Jonathan F. Plehn,

    Affiliation: National Heart, Lung, and Blood Institute, National Institutes of Health, Washington, District of Columbia, United States of America

    X
  • Stephen S. Gottlieb,

    Affiliation: Department of Medicine, University of Maryland, Baltimore, Maryland, United States of America

    X
  • Marc A. Silver,

    Affiliation: Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, United States of America

    X
  • JoAnn Lindenfeld,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Alan B. Miller,

    Affiliation: Division of Cardiology, University of Florida Health Sciences Center, Jacksonville, Florida, United States of America

    X
  • Michel White,

    Affiliation: Research Center, Montreal Heart Institute, Montreal, Quebec, Canada

    X
  • Ryan Walsh,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Penny Nelson,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Allen Medway,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Gordon Davis,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Alastair D. Robertson,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • J. David Port,

    Affiliations: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America, ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • James Carr,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Guinevere A. Murphy,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Laura C. Lazzeroni,

    Affiliation: Department of Psychiatry and Behavioral United States of America, Sciences and of Pediatrics, Stanford University, Stanford, California, United States of America

    X
  • William T. Abraham,

    Affiliation: Ohio State University, Columbus, Ohio, United States of America

    X
  • Stephen B. Liggett,

    Affiliation: Center for Personalized Medicine and Genomics, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America

    X
  • Michael R. Bristow

    Affiliations: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America, ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Published: October 10, 2012
  • DOI: 10.1371/journal.pone.0044324

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.